Lagunita BioSciences LLC
6
13M
3
2
0.50
- Areas of investment
Summary
The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2018. The fund is constantly included in less than 2 deals per year.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Medical. The fund has exact preference in some founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Kedalion Therapeutics, ViewPoint Therapeutics, Verana Health
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Lagunita BioSciences LLC, startups are often financed by Waycross Ventures, Mission Bay Capital, GE Ventures. The meaningful sponsors for the fund in investment in the same round are Mission Bay Capital, GE Ventures, Biomatics Capital Partners. In the next rounds fund is usually obtained by The Rise Fund, Novo Ventures, Mission Bay Capital.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 2
- Follow on index
- 0.50
- Investments by industry
- Health Care (6)
- Biotechnology (4)
- Therapeutics (4)
- Medical (2)
- Analytics (2) Show 1 more
- Investments by region
-
- United States (6)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 0.83
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Kedalion Therapeutics | 15 Nov 2021 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | United States, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.